Tue, Mar 3, 2015, 2:12 PM EST - U.S. Markets close in 1 hr 48 mins

Recent

% | $
Quotes you view appear here for quick access.

J. C. Penney Company, Inc. Message Board

confucious_222 3 posts  |  Last Activity: Jan 21, 2015 10:27 AM Member since: Jul 9, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • confucious_222 by confucious_222 Jan 21, 2015 10:27 AM Flag

    You HAVE to love it!!!
    All the new longs on margin in the futures just got taken to the slaughterhouse

  • confucious_222 by confucious_222 Jan 16, 2015 8:44 PM Flag

    98 cents is greater than 61 cents.
    I would not sell this stock for under $1.00. Now THAT would be crazy.

  • Reply to

    Back down to $2.00?

    by wordlender Dec 9, 2014 9:32 AM
    confucious_222 confucious_222 Dec 22, 2014 9:10 PM Flag

    --(BUSINESS WIRE)--
    Bio-Path Holdings, Inc., (BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma. Bio-Path has a completed preclinical package of toxicity, tissue distribution, pharmacokinetics and efficacy studies. The Company plans to file an Investigational New Drug application (IND) in the first half of 2015.

    Liposomal Bcl-2 (“L-Bcl-2”) is a liposomal encapsulated oligonucleotide targeted to the translation initiation site of human Bcl-2 mRNA. The antisense oligonucleotide in L-Bcl-2 used by Bio-Path Holdings is a nuclease-resistant, hydrophobic analog of phosphodiesters containing the Company’s proprietary P-ethoxy backbone. The main advantage of this structure is the lack of a sulfur moiety, which has been associated with bleeding diathesis. Bcl-2 overexpression has been associated with up to 60 percent of cancers.

JCP
7.92+0.07(+0.89%)2:11 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.